Status:
COMPLETED
Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
Lead Sponsor:
University of California, San Francisco
Conditions:
Soft Tissue Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is to determine whether antibiotic therapy is needed for patients with non-life threatening soft tissue infections. Most patients with these soft tissue infections are presently treated wit...
Detailed Description
The Integrated Soft Tissue Infection Service (ISIS) Clinic at San Francisco General Hospital treats a large number of patients with soft tissue infections, and our data suggest that antibiotics may be...
Eligibility Criteria
Inclusion
- 1\. Patients must have a complicated skin or skin-structure infection that meets disease diagnostic criteria (severity, definition of complicated, and disease).
- SEVERITY: Complicated soft tissue infections must be of sufficient severity to anticipate five or more days of antibiotic therapy.
- DEFINITION OF COMPLICATED (one or more of the following criteria must be met): Infection requires(ed) significant surgical intervention (such as debridement of devitalized tissue, drainage of abscess, removal of foreign body implicated in infection) at the time of enrollment.
- DISEASE: Major Abscess (no open wound). The patient must have all of the following: i) Acute onset within seven days prior to enrollment. ii) Purulent drainage or purulent aspirate. iii) Erythema, induration, or tenderness. iv) Evidence of loculated fluid by physical examination, blind aspiration, or ultrasound that requires intervention (such as aspiration, incision and drainage, excision) at the time of enrollment.
- 2\. A culture must be obtained at the time of enrollment. 3. Patients must be at least 18 years of age. 4. The patient must sign and date a Committee on Human Research-approved informed consent form.
Exclusion
- Any of the following conditions:
- Patients unlikely to survive through the treatment period and evaluations.
- Conditions such as toxic shock syndrome or toxic-like syndrome (Mandell et al. 2000), shock or hypotension (supine systolic blood pressure \<80 mmHg) refractory to fluid or short course pressor challenge (four hours or less) or oliguria (urine output \<20 mL/hr) not responsive to fluid challenge.
- Incisional wound that extends into visceral compartments.
- Suspected or proven contiguous bony or joint involvement.
- Malignant otitis externa.
- Ischemic ulcers or wounds associated with sever arterial insufficiency or gangrene.
- Infection of prosthetic materials or venous catheters that cannot be removed as part of the treatment of the current infection.
- Infection of a full-thickness burn wound or burn wound that is \>20% total body area.
- Surgical/nonsurgical debridement of devitalized tissue, removal of prosthetic material, incision and drainage, suture removal, percutaneous aspiration, packing, dressings, or irrigation (including with antibiotics) that cannot be instituted at the time of enrollment.
- Any known sensitivity to cephalexin.
- Patients with renal compromise.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00187759
Start Date
November 1 2004
End Date
March 1 2005
Last Update
May 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco General Hospital
San Francisco, California, United States, 94115